Based on current trial populations and how the FDA has handled semaglutide and tirzepatide approvals, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, OSA) Adults 18 and older Not pregnant or breastfeeding No history of MTC or MEN 2 Retatrutide will almost certainly launch at a high price point estimates suggest $1,200$1,500 per month at list price
Because they lack the belief and confidence needed to provide these treatments
They cannot substitute for batch-specific COA data or convert a product listing into a claim
Filings claiming myostatin and ActRII pathway combinations with GLP-1 agonists [14] point toward future therapies designed to optimize the quality rather than just quantity of weight loss
Overexposure to UV light can cause inflammation (acne, rashes, sunburn) and hyperpigmentation (dark spots, sun spots, or liver spots)
Rubio J, et al